Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus YOSPRALA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus YOSPRALA.
PANTOPRAZOLE SODIUM vs YOSPRALA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Yosprala is a combination of aspirin (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 and cyclooxygenase-2, thereby reducing thromboxane A2 synthesis and platelet aggregation) and omeprazole (a proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme in gastric parietal cells).
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
YOSPRALA (esomeprazole magnesium and naproxen) is available as delayed-release tablets containing 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole. The typical adult dose is one tablet twice daily, swallowed whole with liquid, at least 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Naproxen: terminal elimination half-life is approximately 14 hours (range 12–17 hours), allowing twice-daily dosing. Esomeprazole: terminal half-life is approximately 1.2–1.5 hours after single dose, increasing to ~1.5–2.5 hours with repeated dosing due to saturation of CYP2C19. Clinical context: naproxen's half-life supports sustained analgesic/anti-inflammatory effect; esomeprazole's shorter half-life requires daily dosing for acid suppression.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
YOSPRALA (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is primarily excreted in urine as unchanged drug (approximately 60%) and as glucuronide conjugates (approximately 30%). Esomeprazole is extensively metabolized; less than 1% of the dose is excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder via metabolites.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor